News
High-Risk Genes for Familial Hemiplegic Migraine Do Not Elevate Epilepsy Risk, Study Shows
February 21st 2025Pathogenic variants in the CACNA1A, ATP1A2, and SCN1A genes were associated with a higher risk of migraine, particularly in heterozygous carriers of loss-of-function and neutral variants.
The Rationale Behind Recently Approved AXS-07 Combination Therapy for Migraine: Stewart Tepper, MD
February 21st 2025The professor of neurology at the Geisel School of Medicine at Dartmouth talked about how the combination therapy involving meloxicam and rizatriptan may provide a more effective approach to treating migraine. [WATCH TIME: 6 minutes]
Oligoclonal Bands in Cerebrospinal Fluid May Signal Higher Relapse Risk in MOGAD
February 20th 2025A recent study reported that the presence of oligoclonal bands in cerebrospinal fluid of patients with myelin oligodendrocyte glycoprotein antibody-associated disease may be associated with a higher risk of relapse.
Navigating the Future of Gene Therapy in Neuromuscular Disorders: John Brandsema, MD
February 20th 2025The pediatric neurologist at Children’s Hospital of Philadelphia provided background on a notable track session at the upcoming MDA Clinical & Scientific Conference covering updates in gene therapy for neuromuscular conditions. [WATCH TIME: 4 minutes]
Managing NMOSD Disease Progression Through Healthy Habits and Holistic Care: Tammy Smith, MD, PhD
February 20th 2025The assistant professor in the neurology department at the University of Utah in Salt Lake City discussed the importance of addressing broader quality-of-life measures in patients with NMOSD beyond just preventing relapses. [WATCH TIME: 3 minutes]
FDA Refuses to File Harmony’s Supplemental NDA of Pitolisant in Idiopathic Hypersomnia
February 20th 2025Marketed as Wakix, the treatment is currently approved in the United States for excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy and for EDS in pediatric patients aged 6 and older.
Advancing Therapeutic Knowledge of Genetic Influence in ALS: Matthew B. Harms, MD
February 19th 2025The associate professor of neurology at Columbia University gave clinical insight on what neurologists and other neuromuscular specialists can expect from the ALS/frontotemporal dementia track at this year’s MDA Clinical & Scientific Conference. [WATCH TIME: 3 minutes]
Solid Reports Positive Data for SGT-003 Gene Therapy in Phase 1/2 Trial of Duchenne
February 18th 2025After 90 days of treatment, investigators observed positive findings on microdystrophin expression, as well as reductions in markers of muscle injury and stress, and muscle breakdown and dystrophic regeneration.
ALS, Genetics, and New Horizons: What to Expect at the 2025 MDA Conference
February 18th 2025Matthew B. Harms, MD, an associate professor of neurology at Columbia University Irving Medical Center, an MDA Care Center, gave clinical insights on the advances in ALS genetic research and what clinicians can expect from the ALS/FTD track at the 2025 MDA Clinical & Scientific Conference.
Expanding the Development of Cell Therapy for Muscular Dystrophy: Rita Perlingeiro, PhD
February 18th 2025The Lillehei professor in stem cell and regenerative cardiovascular medicine at the University of Minnesota talked about the potential of investigating inducted pluripotent stem cells in neuromuscular diseases at MDA’s 2025 conference. [WATCH TIME: 8 minutes]
Meta-Analysis Reveals Patients With Epilepsy at Increased Risk for Psychiatric Disorders
February 18th 2025Findings showed that patients with epilepsy were significantly more likely to experience a range of psychiatric disorders, including depression, anxiety, and substance use disorders, compared with those without the condition.
Key Considerations When Incorporating Stroke Trial Data Into Clinical Practice: J Mocco, MD, MS
February 17th 2025The director of the Cerebrovascular Center at Mount Sinai highlighted key differences in patient selection criteria and trial designs that may influence how stroke treatment data is applied in clinical practice. [WATCH TIME: 5 minutes]
Evolving Parkinson Disease Care in the Digital Age of Neurology: Sheryll Baltazar, NP-C
February 17th 2025The nurse practitioner at the Parkinson’s and Movement Disorders Center at Stony Brook Medicine discussed the increasing role of artificial intelligence in neurology, specifically movement disorders. [WATCH TIME: 5 minutes]
New Functional MRI Model Shows High Accuracy in Differentiating Between MS and NMOSD
February 16th 2025A newly developed advanced fMRI-based classification model demonstrated efficacy in distinguishing multiple sclerosis from neuromyelitis optica spectrum disorder, potentially having the ability to improve diagnostic accuracy.
Engaging the Clinical and Patient DMD Community at the 2025 FUTURES Conference: Heather Medlin, MSW
February 16th 2025The associate vice president of community outreach at CureDuchenne talked about events like the 2025 FUTURES National Conference that aim to bring individuals from the Duchenne community together. [WATCH TIME: 6 minutes]
